英特格拉生命科学（Integra Lifesciences，股票代码：IART）今日盘中大跌5.27%，引发市场关注。此次下跌主要受到多家知名投资银行下调目标价的影响。
根据最新消息，富国银行（Wells Fargo）维持对英特格拉生命科学的"持股观望"评级，但将目标价从25.00美元大幅下调至13.00美元。同时，摩根大通（JPMorgan）也维持了对该公司的"减持"评级，并将目标价从24.00美元下调至12.00美元。
这些投资银行的评级调整反映了市场对英特格拉生命科学未来前景的担忧。作为一家专注于再生疗法、肢体骨科和神经外科应用的医疗设备公司，英特格拉生命科学可能面临行业竞争加剧或业务发展不及预期等挑战。投资者应密切关注公司后续的财务表现和业务发展情况，以评估其长期投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.